A new study in the Journal of the American Heart Association reveals that heart-healthy lifestyle factors are linked to younger biological age and lower cardiovascular disease risk through DNA methylation.
US FDA grants breakthrough therapy status for Nuvalent’s NVL-655
NVL-655 is intended to treat locally advanced or metastatic ALK-positive NSCLC patients previously treated with two or more ALK TKIs. Credit: Sebastian Kaulitzki / Shutterstock.com.